NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...

Noting the unique nature of pediatric brains, which are still developing, the importance that standard anesthesia practice places on minimizing the dosage of drugs needed to maintain anesthesia, and ...

Masimo Corporation MASI recently announced the findings of a prospective study published in Frontiers in Neurology. The study evaluated whether general anesthesia guided by Masimo SedLine Brain ...

In a recent breakthrough, Masimo Corporation MASI announced that its Next Generation SedLine brain function monitoring has received clearance from the FDA. The device will provide clinicians real-time ...

EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure ...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today FDA clearance of Next Generation SedLine ® brain function monitoring. SedLine helps clinicians monitor the state of the brain ...

(BUSINESS WIRE )--Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical ...

Masimo, a global medical technology company developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and ...

Children monitored with SedLine were exposed to an average of 1.4 MAC hours less sevoflurane and had a 14% lower incidence rate of PAED. On average, they regained consciousness 53% sooner and were ...